BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) saw its stock soar 7.83% in the after-hours trading session on Wednesday, following the company's impressive fourth-quarter results and an optimistic outlook for the full year 2025.
In the fourth quarter, BioMarin reported adjusted earnings of $0.92 per diluted share, significantly outperforming analysts' expectations of $0.53 per share. The company's revenue for the quarter stood at $747.3 million, surpassing the consensus estimate of $713.4 million.
The strong performance was driven by robust sales of BioMarin's key products, including VOXZOGO for achondroplasia, which saw a 42% year-over-year increase in revenue to $208 million during the quarter. The company's Enzyme Therapies portfolio also contributed significantly, with sales rising 9% year-over-year.
Looking ahead to 2025, BioMarin provided an optimistic outlook, projecting non-GAAP earnings per share in the range of $4.20 to $4.40 on revenue between $3.1 billion and $3.2 billion. This guidance surpassed analysts' expectations of $4.15 in earnings per share and $3.10 billion in revenue.
The company's solid performance and upbeat guidance reflect its strategic focus on expanding the global reach of its innovative therapies and advancing its robust pipeline of potential treatments for rare genetic disorders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。